secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2026-02-27T23:59:59+00:00
Accession:  0001213900-26-021120
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio pipeline update: CORDStrom Phase 3 data and XPro1595 FDA alignment for Phase 2b/3 AD trial
--------------------------------------------------------------------------------

- CORDStrom Phase 3 shows improvements in itch, pain, and skin scores in RDEB; MAA submission expected Q3 2026 for UK.
- XPro1595 Phase 2 MINDFuL trial met FDA end-of-Phase 2 meeting; adaptive Phase 2b/3 design with CDR-SB primary accepted.
- CORDStrom potential TAM >$1.4B; annual COG $120-180K; anticipated reimbursement ~$700K per year.
- XPro1595 showed zero ARIA events in high-risk APOE4+ population; Phase 3 readiness targeted for 2027.
- CORDStrom regulatory milestones: RPDD and ODD approved, pre-MAA doc submitted, BLA/MAA submissions planned in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026021120/0001213900-26-021120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390026021120/ea02262026-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-021120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer